BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...also tend to rocket upwards on the first day of trading. The most recent IPO, HitGen...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...has launched scores of partnerships, with Hitgen Inc. among the most prolific dealmakers (see “ Hitgen’s...
BioCentury | Apr 30, 2020
Finance

Shiyu backs Mabwell’s massive series A following close of second fund

...for Allist Pharmaceuticals. The most recent of the firm’s portfolio companies to go public is HitGen...
BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

...listing in Shanghai. Source: Hong Kong and Shanghai exchanges. Jin Li, chairman and CEO of HitGen...
BioCentury | Feb 4, 2020
Product Development

China faces clinical delays during coronavirus outbreak

...data management, drug supply monitoring, and imaging consultation. Jin Li, chairman and CEO of Chengdu-based HitGen...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Co. Ltd. (Shanghai) 8/14/19 $285.4 Mkt (drug) Alphamab Oncology Ltd. (HKEX) 7/15/19 TBD Ph II HitGen...
BioCentury | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

...to pay attention to this technology,” said Jin Li, chairman and CEO of DEL company HitGen...
...technology through deals with HitGen and competing DEL providers X-Chem Inc. and Nuevolution AB (see “HitGen’s...
...Nuevolution was acquired by Amgen Inc. this year for about SEK1.6 billion ($166.8 million). HitGen...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...come from a short list of mainland Chinese companies with active applications for STAR, including HitGen...
BioCentury | Jul 31, 2019
Financial News

Chipscreen sets pace for biotech IPOs in Shanghai

...and Hunan Nucien Pharmaceutical Co. Ltd (Changsha, China). The STAR market’s IPO queue also includes HitGen...
BioCentury | Jul 12, 2019
Financial News

HitGen joins growing Shanghai IPO queue

...The Shanghai Stock Exchange accepted an application from HitGen this week to list on its new...
...to sell at least 40 million shares and raise up to RMB660 million ($95.9 million). HitGen’s...
...Sciences Inc. (NASDAQ:GILD) and Almirall S.A. (Madrid:ALM) (see “ HitGen’s DNA for Small Molecules ”). HitGen...
Items per page:
1 - 10 of 30
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...also tend to rocket upwards on the first day of trading. The most recent IPO, HitGen...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...has launched scores of partnerships, with Hitgen Inc. among the most prolific dealmakers (see “ Hitgen’s...
BioCentury | Apr 30, 2020
Finance

Shiyu backs Mabwell’s massive series A following close of second fund

...for Allist Pharmaceuticals. The most recent of the firm’s portfolio companies to go public is HitGen...
BioCentury | Feb 11, 2020
Finance

Coronavirus could stall China IPOs

...listing in Shanghai. Source: Hong Kong and Shanghai exchanges. Jin Li, chairman and CEO of HitGen...
BioCentury | Feb 4, 2020
Product Development

China faces clinical delays during coronavirus outbreak

...data management, drug supply monitoring, and imaging consultation. Jin Li, chairman and CEO of Chengdu-based HitGen...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Co. Ltd. (Shanghai) 8/14/19 $285.4 Mkt (drug) Alphamab Oncology Ltd. (HKEX) 7/15/19 TBD Ph II HitGen...
BioCentury | Sep 13, 2019
Tools & Techniques

Getting higher-quality hits out of DNA-encoded libraries

...to pay attention to this technology,” said Jin Li, chairman and CEO of DEL company HitGen...
...technology through deals with HitGen and competing DEL providers X-Chem Inc. and Nuevolution AB (see “HitGen’s...
...Nuevolution was acquired by Amgen Inc. this year for about SEK1.6 billion ($166.8 million). HitGen...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...come from a short list of mainland Chinese companies with active applications for STAR, including HitGen...
BioCentury | Jul 31, 2019
Financial News

Chipscreen sets pace for biotech IPOs in Shanghai

...and Hunan Nucien Pharmaceutical Co. Ltd (Changsha, China). The STAR market’s IPO queue also includes HitGen...
BioCentury | Jul 12, 2019
Financial News

HitGen joins growing Shanghai IPO queue

...The Shanghai Stock Exchange accepted an application from HitGen this week to list on its new...
...to sell at least 40 million shares and raise up to RMB660 million ($95.9 million). HitGen’s...
...Sciences Inc. (NASDAQ:GILD) and Almirall S.A. (Madrid:ALM) (see “ HitGen’s DNA for Small Molecules ”). HitGen...
Items per page:
1 - 10 of 30